Opicapone: A Review in Parkinson’s Disease

@article{Scott2016OpicaponeAR,
  title={Opicapone: A Review in Parkinson’s Disease},
  author={L. Scott},
  journal={Drugs},
  year={2016},
  volume={76},
  pages={1293-1300}
}
Oral opicapone (Ongentys®), a potent, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson’s disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on those combinations. In 14- to 15-week, double-blind, multinational trials and in 1-year, open-label extension studies in this patient population, opicapone was an… Expand
Opicapone in Parkinson’s disease: a profile of its use
TLDR
With its convenient once-daily regimen, oral opicapone is an emerging COMT inhibitor option for use as adjunctive therapy to levodopa/DDCI therapy in adults with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Expand
Opicapone: A Review in Parkinson’s Disease
TLDR
Given its efficacy and safety profile, adjunctive opicapone remains an important option in the management of adults with PD and EoD motor fluctuations who cannot be stabilized on preparations of L-dopa/DDCI. Expand
Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
TLDR
Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. Expand
Clinical Utility of Opicapone in the Management of Parkinson’s Disease: A Short Review on Emerging Data and Place in Therapy
TLDR
Opicapone’s lifecycle, its clinical pharmacological data, safety, tolerability and pharmacovigilance evidence, and its role in the management of motor fluctuations in PD are discussed, as well as its emerging place in international recommendations. Expand
Opicapone for the treatment of Parkinson’s disease: an update
TLDR
This article summarizes knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016–2019), and details the pharmacological profile of OPC and the results of completed clinical trials. Expand
Opicapone for the Treatment of Parkinson's Disease: a review.
TLDR
Opicapone is a safe and efficacious option to combat motor fluctuations for PD patients taking levodopa and should be considered in combination with other augmenting medications with different mechanisms of action, to help treat motor and non-motor fluctuations in PD. Expand
Opicapone: A third generation COMT inhibitor
TLDR
Most common treatment-emergent adverse events for opicapone were dyskinesia, falls, insomnia, and elevated blood creatine phosphokinase levels; it has not been associated with severe hepatic impairment. Expand
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
TLDR
Recent investigations about non-dopaminergic central nervous system (CNS) receptor ligands that have been identified to have therapeutic potential for the treatment of motor and non-motor symptoms of Parkinson’s disease are focused on. Expand
Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
Opicapone, a recently introduced catechol‐o‐methyl transferase (COMT) inhibitor has the advantage of being administered once daily, and has pharmacokinetic data to indicate it offers a greater degreeExpand
[Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
TLDR
Device-aided therapies should be considered in patients with severe motor complications who receive at least 750-1000 mg levodopa daily, divided minimum 5×/day, by multidisciplinary teams in order to make the best decision for further action. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 36 REFERENCES
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
TLDR
A randomised, double-blind, placebo-controlled and active-controlled trial of opicapone as an adjunct to levodopa in patients with Parkinson's disease with end-of-dose motor fluctuations, finding that treatment with opiapone 50 mg was superior to placebo. Expand
Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study
TLDR
Opicapone, a novel third‐generation catechol‐O‐methyltransferase inhibitor for use as adjunctive therapy in levodopa‐treated Parkinson's disease patients, was investigated on cardiac repolarization in healthy adult volunteers, confirming that opicapone has no QT‐prolonging effect. Expand
Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
TLDR
Opicapone was well-tolerated and presented dose-proportional kinetics, and sustained inhibition of erythrocyte soluble COMT activity was demonstrated, providing a basis for further clinical development of opicapone. Expand
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
TLDR
Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen. Expand
Effect of 3 Single‐Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol‐O‐Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
TLDR
It was concluded that OPC is a new COMT inhibitor that significantly decreased COMT activity and increased systemic exposure to levodopa in PD patients with motor fluctuations. Expand
Effect of moderate liver impairment on the pharmacokinetics of opicapone
TLDR
The bioavailability of an orally administered single dose of 50 mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect. Expand
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
TLDR
It is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson’s disease patients. Expand
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
TLDR
OPC is a promising new COMT inhibitor and deserves further clinical evaluation in larger samples of patients with PD on levodopa treatment with motor fluctuations, but the exploratory analysis performed shows improvement in various motor outcomes. Expand
Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects
TLDR
The PK and PD profiles of OPC were similar in the Japanese and white populations, thus, ethnicity and COMT polymorphisms had no significant impact on the OPC PK andPD in the conditions of the study. Expand
Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease
TLDR
This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response tolevodopa in Parkinson's disease patients with motor fluctuations. Expand
...
1
2
3
4
...